A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore (DiabCare Asia)

November 21, 2016 updated by: Novo Nordisk A/S

DiabCare Asia 2008. A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and To Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia

This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control and complications in diabetic subjects in Asia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

854

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Singapore
      • Singapore, Singapore, 307684
        • Novo Nordisk Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with diabetes mellitus (both type 1 and type 2) being treated at general hospitals, diabetes clinics and referral clinics will be selected according to the inclusion and exclusion criteria.

Description

Inclusion Criteria:

  • Diabetic patients registered in the particular centre for more than 12 months
  • Patients should have visited the centre at least once in the last 3-6 months apart from the initial visit
  • Patients willing to sign informed consent form

Exclusion Criteria:

  • Repetition of any patient as patients should not be included twice for any reason
  • Unwilling to participate or unable to comply with protocol requirements

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
A
Other: No treatment given
No treatment given

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Mean duration of diabetes in type 1 and type 2 patients respectively
Time Frame: at baseline visit/study start
at baseline visit/study start
Mean age of onset of type 1 and 2 diabetes mellitus
Time Frame: at baseline visit/study start
at baseline visit/study start
Mean duration of treatment of type 2 DM
Time Frame: at baseline visit/study start
at baseline visit/study start
Percentage of patients on Insulin and OAD therapy
Time Frame: at baseline visit/study start
at baseline visit/study start
Mean FPG and PPG of diabetic patients
Time Frame: at baseline visit/study start
at baseline visit/study start
Mean HbA1c of diabetic patients
Time Frame: at baseline visit/study start
at baseline visit/study start
Percentage of diabetic patients having dyslipidemia and hypertension
Time Frame: at baseline visit/study start
at baseline visit/study start
Percentage of diabetic patients having cardiovascular complications
Time Frame: at baseline visit/study start
at baseline visit/study start
Percentage of diabetic patients having peripheral vascular disease
Time Frame: at baseline visit/study start
at baseline visit/study start
Percentage of diabetic patients having diabetic eye complications
Time Frame: at baseline visit/study start
at baseline visit/study start
Percentage of diabetic patients having diabetic nephropathy
Time Frame: at baseline visit/study start
at baseline visit/study start
Percentage of diabetic patients with HbA1c target below or equal to 7.0%
Time Frame: at baseline visit/study start
at baseline visit/study start
Percentage of diabetic patients with HbA1c target below or equal to 6.5%
Time Frame: at baseline visit/study start
at baseline visit/study start

Secondary Outcome Measures

Outcome Measure
Time Frame
Duration of diabetes associated with highest number of diabetic complications
Time Frame: at baseline visit/study start
at baseline visit/study start
Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)
Time Frame: at baseline visit/study start
at baseline visit/study start
Patients' perception will be analysed through Patient questionnaire measuring - Psychological well-being, Quality of life, Patients' compliant to treatment
Time Frame: at baseline visit/study start
at baseline visit/study start
Physician perception of diabetes and its management will be analysed through Physician questionnaire measuring awareness about - HbA1c test and its goal, Anti-diabetic treatment, Barriers towards optimum diabetes control
Time Frame: at baseline visit/study start
at baseline visit/study start

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novo Nordisk A/S

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2009

Primary Completion (Actual)

April 1, 2009

Study Completion (Actual)

April 1, 2009

Study Registration Dates

First Submitted

January 30, 2009

First Submitted That Met QC Criteria

February 3, 2009

First Posted (Estimate)

February 4, 2009

Study Record Updates

Last Update Posted (Estimate)

November 22, 2016

Last Update Submitted That Met QC Criteria

November 21, 2016

Last Verified

November 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • INS-3710

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe